The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2021 | The unmet needs of essential thrombocythemia and polycythemia vera patients
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, outlines unmet needs in the fields of essential thrombocythemia and polycythemia vera by highlighting limitations of current treatments and the prospects of novel therapies. Dr Gerds specifically discusses the issue of symptom burden which the current treatment options phlebotomy, hydroxyurea, and anagrelide fail to address. Dr Gerds further talks on the need for more disease-modifying treatments which can reduce allele burden, target the disease on a clonal level, and delay progression. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
